Our Pipeline
Development Validation Trial Regulatory Approval Commercialisation

Nova Satra is developing a pipeline of molecular diagnostics tests for breast, colon, lung, prostate and stomach cancers, using the NovaTect™ epigenetic technology to monitor Asian-specific epigenetic biomarkers associated with these cancers.


As the population in Asia grows and ages, incidence of and mortality from cancer is also on the rise. Nova Satra has identified these indications among the highest unmet need in the region. NovaTect™ may be used to more quickly and accurately detect the presence of these cancers, leading to earlier diagnosis and improved outcomes for patients.

The incidence of cancer in Asia is estimated to increase by 41% and mortality is expected to rise by 44%
The top three causes of cancer death in women in Asia are lung, breast, and stomach cancer